Who We Are and What We Do

The Leukemia & Lymphoma Society exists to find cures and ensure access to treatments for all blood cancer patients. We are the voice for the more than 1.3 million people in the US living with or in remission from a blood cancer: leukemia, lymphoma, myeloma or another malignancy of the blood.

Every three minutes someone is diagnosed with a blood cancer.


Research

Since our inception in 1949 we have invested more than $1.2 billion in blood cancer research. Our investment has played a role in most of the therapies that are used to treat blood cancer patients today and many of these therapies are helping patients with other cancers and serious diseases.

Advances such as chemotherapy, bone and stem cell transplantation, and more recently, targeted therapies that precisely target the genetic drivers of the cancer while sparing healthy tissue, and therapies that harness the body’s own immune system to fight cancer, began with the blood cancers.

Between 2000 and 2017, approximately 40% of cancer-fighting therapies approved by the FDA were first approved to treat blood cancer patients and many of these are helping other patients. For example, Gleevec®, first approved to treat patients with chronic myeloid leukemia, is now approved for certain rare forms of stomach and skin cancers, and Rituxan®, first approved to treat lymphoma patients, is now approved to treat patients with rheumatoid arthritis and other autoimmune diseases. These drugs, and many others first approved for blood cancer patients, are being tested for many other types of cancers and diseases.

Through our Therapy Acceleration Program (TAP®) we strategically partner with biotechnology companies and academic researchers to help advance promising therapies into clinical trials so they can get to patients faster.
The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS Mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has chapters throughout the United States and Canada. To learn more, www.lls.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET

LLS launched its groundbreaking precision medicine Beat AML® Master Trial in October 2016, leading the offensive against acute myeloid leukemia, one of the most deadly blood cancers that has seen few improvements in treatment in more than 40 years.

**Patient Access**

Our Information Resource Center is a toll-free call center staffed with master’s degree level healthcare professionals armed with up-to-date information about blood cancers and treatment options. The IRC fields approximately 26,000 inquiries a year and performs hundreds of clinical trials searches for patients.

Our Co-Pay Assistance Program is designed to help patients afford their health insurance co-pays and insurance premiums. Since its inception in 2007 the co-pay program has provided $362 million in support and helped more than 79,000 patients.

Our Patti Robinson Kaufmann program is a peer-to-peer program in which trained volunteer blood cancer survivors are matched with a newly diagnosed patient to share their experiences; and the Susan Lang Pay-it-Forward Travel Assistance Program helps patients with transportation/travel to help them get to their health care providers for their blood cancer related treatments.

**Policy and Advocacy**

Our policy and advocacy team works to secure both federal and state laws to ensure access, by limiting out of pocket costs for treatments. For example, we have helped pass laws in 43 states plus Washington D.C. ensuring equity in cost-sharing for thousands of patients who rely on orally-administered cancer treatments.

LLS has played a critical role in advancing the 21st Century cures bill, designed to accelerate cures through FDA reform.

LLS has built a nationwide grassroots network to empower blood cancer patients and their loved ones to affect real change in treatment and care through: currently more 100,000 grassroots advocates across the country.